These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 28125180)

  • 1. A Direct Oral Anticoagulant as a Cost Effective Alternative to Warfarin for Treatment of Provoked Venous Thrombosis.
    Courtney W; Groarke E; Conway J; Conway E; Bourke D; Saunders J; Watts M; O'Keefe D
    Ir Med J; 2016 Oct; 109(9):466. PubMed ID: 28125180
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rivaroxaban vs. warfarin on extended deep venous thromboembolism treatment: A cost analysis.
    Diken AI; Yalçınkaya A; Hanedan MO; Erol ME; Ercen Diken Ö
    Phlebology; 2018 Feb; 33(1):53-59. PubMed ID: 28056701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Healthcare costs associated with rivaroxaban or warfarin use for the treatment of venous thromboembolism.
    Coleman CI; Baugh C; Crivera C; Milentijevic D; Wang SW; Lu L; Nelson WW
    J Med Econ; 2017 Feb; 20(2):200-203. PubMed ID: 27780397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A cost-analysis model for anticoagulant treatment in the hospital setting.
    Mody SH; Huynh L; Zhuo DY; Tran KN; Lefebvre P; Bookhart B
    J Med Econ; 2014 Jul; 17(7):492-8. PubMed ID: 24773068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Costs of hospital visits among patients with deep vein thrombosis treated with rivaroxaban and LMWH/warfarin.
    Merli GJ; Hollander JE; Lefebvre P; Laliberté F; Raut MK; Germain G; Bookhart B; Pollack CV
    J Med Econ; 2016; 19(1):84-90. PubMed ID: 26390315
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health Economic Analysis of Rivaroxaban and Warfarin for Venous Thromboembolism Management in Chinese Patients.
    Fung KP; Chan KH; Ng V; Tsui PT; You JHS
    Cardiovasc Drugs Ther; 2019 Jun; 33(3):331-337. PubMed ID: 30888571
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
    Mensch A; Stock S; Stollenwerk B; Müller D
    Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Budget impact analysis of rivaroxaban vs. warfarin anticoagulation strategy for direct current cardioversion in non-valvular atrial fibrillation patients: the MonaldiVert Economic Study.
    Russo V; Rago A; Papa AA; Bianchi V; Tavoletta V; DE Vivo S; Cavallaro C; Nigro G; D'Onofrio A
    Minerva Cardioangiol; 2018 Feb; 66(1):1-5. PubMed ID: 28948752
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost of Treating Venous Thromboembolism With Heparin and Warfarin Versus Home Treatment With Rivaroxaban.
    Kahler ZP; Beam DM; Kline JA
    Acad Emerg Med; 2015 Jul; 22(7):796-802. PubMed ID: 26111453
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban versus Heparin Bridging to Warfarin Therapy: Impact on Hospital Length of Stay and Treatment Costs for Low-Risk Patients with Pulmonary Embolism.
    Weeda ER; Kohn CG; Peacock WF; Fermann GJ; Crivera C; Schein JR; Coleman CI
    Pharmacotherapy; 2016 Oct; 36(10):1109-1115. PubMed ID: 27548074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient-reported treatment satisfaction and budget impact with rivaroxaban vs. standard therapy in elective cardioversion of atrial fibrillation: a post hoc analysis of the X-VeRT trial.
    Hohnloser SH; Cappato R; Ezekowitz MD; Evers T; Sahin K; Kirchhof P; Meng IL; van Eickels M; Camm AJ;
    Europace; 2016 Feb; 18(2):184-90. PubMed ID: 26487668
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
    Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
    Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic analysis of rivaroxaban for the treatment and long-term prevention of venous thromboembolism in Portugal.
    Santos IF; Pereira S; McLeod E; Guillermin AL; Chatzitheofilou I
    Acta Med Port; 2014; 27(5):615-24. PubMed ID: 25409218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of differences in medical costs when new oral anticoagulants are used for the treatment of patients with non-valvular atrial fibrillation and venous thromboembolism vs warfarin or placebo in the US.
    Amin A; Bruno A; Trocio J; Lin J; Lingohr-Smith M
    J Med Econ; 2015 Jun; 18(6):399-409. PubMed ID: 25586203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of acute lower extremity deep vein thrombosis with rivaroxaban compared to warfarin.
    Houghton DE; Lekah A; Macedo TA; Hodge D; Saadiq RA; Little Y; Casanegra AI; McBane RD; Wysokinski WE
    J Thromb Thrombolysis; 2020 Feb; 49(2):199-205. PubMed ID: 31422520
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indirect comparison and cost-utility of dabigatran etexilate and rivaroxaban in the treatment and extended anticoagulation of venous thromboembolism in a UK setting.
    Jugrin AV; Hösel V; Ustyugova A; De Francesco M; Lamotte M; Sunderland T
    J Med Econ; 2016; 19(1):1-10. PubMed ID: 26390231
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relation of Risk of Stroke in Patients With Atrial Fibrillation to Body Mass Index (from Patients Treated With Rivaroxaban and Warfarin in the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation Trial).
    Balla SR; Cyr DD; Lokhnygina Y; Becker RC; Berkowitz SD; Breithardt G; Fox KAA; Hacke W; Halperin JL; Hankey GJ; Mahaffey KW; Nessel CC; Piccini JP; Singer DE; Patel MR
    Am J Cardiol; 2017 Jun; 119(12):1989-1996. PubMed ID: 28477860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Shorter Hospital Stays and Lower Costs for Rivaroxaban Compared With Warfarin for Venous Thrombosis Admissions.
    Margolis JM; Deitelzweig S; Kline J; Tran O; Smith DM; Bookhart B; Crivera C; Schein J
    J Am Heart Assoc; 2016 Oct; 5(10):. PubMed ID: 27792638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Policy Change for Deep Vein Thrombosis: Effects on Length of Stay and Hospitalization Costs of Moving From Warfarin to Direct Oral Anticoagulants.
    Porath AD; Clodfelter S; Slaton T; Bookhart BK; Kozma CM; Rand ML; Bloch MJ
    Clin Ther; 2019 Feb; 41(2):269-279. PubMed ID: 30642614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.